placeholder newsslider


New Technologies for Outcome Measures in Uveal Melanoma

Basel Series of Special Interest Focus Groups (SIFG) - „New Technologies for Outcome Measures in Uveal Melanoma” In Collaboration with the European Ocular Oncology Group and the International Society of Ocular Oncology

U.K. and Swiss researchers left in limbo with European grants

Restrictions on first grants from Horizon Europe highlight ongoing diplomatic disputes

Science's 2021 Breakthrough of the Year

Researchers have shown that artificial intelligence (AI)-driven software can churn out accurate protein structures by the thousands—an advance and is Science’s 2021 Breakthrough of the Year.

New technology streamlines the development of gene therapy for genetic blinding disorders

A novel computational platform developed by researchers from the University of Pittsburgh School of Medicine identifies top-performing viral vectors that could deliver gene therapies to the retina with maximum efficiency and precision.

Alcon to acquire Ivantis for $475 million

Alcon announced plans to acquire glaucoma surgery device maker Ivantis in a $475 million deal.

New kind of artificial lens may help patients avoid glasses after cataract surgery

Cataract surgery is one of the most successful medical procedures performed in the United States, with nearly 4 million Americans choosing to have their cataracts removed every year. While the procedure has a success rate of about 97 percent, it is not uncommon for people to still need glasses after surgery, especially reading glasses.

2021 Best Program results: Wilmer Eye Institute grabs top spot

The year 2021 saw the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, snaring the top spot in the Overall Best Program category.

RetinAward 2021 for Mathieu Quinodoz

Mathieu Quinodoz, bioinformatics researcher in our Ophthalmic Genetics Group led by Carlo Rivolta, wins CHF 30 000 to support his project: «Increasing the molecular diagnostic rate of inherited retinal degenerations and other retinal diseases by combining high-throughput sequencing with an extensive analytical pipeline».

Iceland and Norway are the first countries associated to Horizon Europe

Iceland and Norway have formally become associated to Horizon Europe, enabling entities in those two countries to participate in Europe’s €95.5 billion research and innovation programme, under the same conditions as entities from the EU Member States.

Closer Collaboration between EC and European Union Intellectual Property Office

The Commission and the European Union Intellectual Property Office commit to closer collaboration on Intellectual Property to support the market uptake of research results

First Place of the OSA2021

Congratulations! After having won the Swiss OpthAward 2021, Magdalena Renner, Head of the IOB Human Organoid Platform won the first place of the VSY Biotechnology Ophthalmology Star Awards (OSA) 2021.

Turkey joins the Horizon Europe, Erasmus+ and Solidarity Corps programmes

The Commission and Turkey signed three agreements granting association status to EU programmes for the period 2021-2027

Optimism Health Group Expands its Footprint with VisionCall acquisition

Optimism Health Group, a healthcare investment business, has recently completed the acquisition of VisionCall, the UK's leading provider of eye care services in care homes. The acquisition came in line with Optimism’s plans to expand its footprint in the fast-growing market for healthcare products and clinical services to older people.

DED in American veterans

earLab Corp. and MellingMedical are teaming up to empower physicians to more effectively diagnose dry eye disease (DED) among veterans. "We are excited to bring osmolarity testing to America's veterans and help support their patient care and therapy decisions," Chris Melling, founder and CEO of MellingMedical, said in a statement.

Companies announce eye care collaboration

AbbVie and REGENXBIO announced a strategic partnership to develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases.